Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 2,054.18 ($27.57) and traded as high as GBX 2,086 ($27.99). Hikma Pharmaceuticals shares last traded at GBX 2,068.16 ($27.75), with a volume of 410,972 shares trading hands.
Analyst Ratings Changes
A number of research analysts have recently commented on HIK shares. Berenberg Bank reaffirmed a "buy" rating and set a GBX 2,560 ($34.35) price objective on shares of Hikma Pharmaceuticals in a research note on Monday, March 10th. JPMorgan Chase & Co. reaffirmed an "overweight" rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th.
Get Our Latest Report on HIK
Hikma Pharmaceuticals Stock Performance
The stock's 50 day moving average price is GBX 2,018.76 and its 200 day moving average price is GBX 2,054.18. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The company has a market cap of £5.74 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 2.38 and a beta of 0.41.
Insider Activity
In other news, insider Said Darwazah sold 13,863 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.69), for a total transaction of £296,390.94 ($397,733.41). Also, insider Victoria Hull sold 2,777 shares of the business's stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of GBX 1,800 ($24.15), for a total value of £49,986 ($67,077.29). Corporate insiders own 30.54% of the company's stock.
About Hikma Pharmaceuticals
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
